Odevixibat: First Approval

Odevixibat (Bylvay (TM)) is a small molecule inhibitor of the ileal bile acid transporter being developed by Albireo Pharma, Inc. for the treatment of various cholestatic diseases, including progressive familial intrahepatic cholestasis (PFIC). In July 2021, odevixibat received its first approval in the EU for the treatment of PFIC in patients aged >= 6 months, followed shortly by its approval in the USA for the treatment of pruritus in patients aged >= 3 months with PFIC. Odevixibat is also in clinical development for the treatment of other cholestatic diseases, including Alagille syndrome and biliary atresia, in various countries. This article summarizes the milestones in the development of odevixibat leading to this first approval for PFIC.

Automated summary

Odevixibat, a small molecule inhibitor of the ileal bile acid transporter, has received approvals in the EU and USA for the treatment of PFIC and pruritus associated with PFIC. It is also in clinical development for other cholestatic diseases in various countries.